Latest News and Press Releases

Applied Biologics expands national commercial payer engagement strategy for XWRAP® to broaden patient access.

Applied Biologics extends longstanding system-wide agreement with Providence Health & Services for XWRAP®.

Applied Biologics initiates multi-center real-world outcomes study of XWRAP® across chronic wound types.

Applied Biologics announces submission of XWRAP® translational research abstract to SAWC Fall 2026.

Applied Biologics announces manufacture of its first research construct for the preclinical DMOAD Gene Therapy Program.

Applied Biologics introduces ECM Preservation Technology™ (EPT™), the proprietary manufacturing platform behind XWRAP®.

Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.

Applied Biologics expands strategic focus to surgical applications of XWRAP® across multiple specialties.

Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.

Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.